Objectives
The article focuses on the three groups of medications for treating asthma, such as new ultra-long-acting beta agonists (ultra-LABAs), short-acting beta agonists (SABAs), and long-acting beta agonists (LABAs) (Cerreta 20). The author also explores the information that can either support or withdraw the necessity of using the above-enumerated beta-2 agonists for treating patients with lung malfunction.
Methods/Approaches
In order to define which medication suits best the treatment of asthma, the article sheds light to such aspects as mechanisms of action, commonly used agonists, as well as define treatment challenges for asthma. By reviewing the testing procedures and evaluating the previously introduced reports and research, the scholar also discusses how patients react to various terms of treatment. Further deliberations are devoted to the analysis of each of the introduced medications to define how effectively they can be used. The discussion is also centered on COPD and its treatment, particularly on the peculiarities of the symptoms and how they differ from those of asthma.
Results
During the studies, the researcher has found that SABAs contain the joint that creates the link with beta-2 receptors. The remaining part of the medication molecule is assimilated in the aqueous elements. The reactions last from 4 to 6 hours. Ultra-LABAs and LABAs have a tail that is instated into the cell membrane. The substance moves along the cell wall to reach a beta-2 receptor (Cerreta 20). As a result, two links are created.
The head of SABAs creates a bong with the receptor and the tail is included into cell exosite that reaches beta-2 agonist. It has been found that LABAs and ultra-LABAs taking is connected with the higher risk of mortality in case the drug is used in mono therapy because long-term use of medication leads to down regulation. Therefore, SABAs are more effective in treating asthma. In contrast, COPD treatment is much more efficient in case LABAs and ultra-LABAs are used for intervention.
Conclusions
The research has discovered that mono therapy is not effective in treating respiratory disorders because they impose certain risks for health. Specifically, a combination of long-term and short-term drug intake could provide the best opportunities for reducing the symptoms of asthma and COPD (Cerreta 24). Efficient management of medical therapy stands at the core of successful management of patients. Each inhalation device should be considered and tested properly because it is used for treatment. Evaluation of qualities and chemical process support the use of the drugs under analysis.
Works Cited
Cerreta, Scott. Examining the Evidence for Using SABAs and LABAs. Chronic Disease Manager, (2012): 20-24. Print.